Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
None USD 0.00(0%)
Last update at 2024-11-21T21:07:52.447950Z
Market Cap
591.47M
P/E
86.43

Momentum Score

…

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
12.55
Low
22.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
30.98
Dividend Yield
-
Revenue TTM
1119.93M
Revenue Per Share
38.39
Gross Profit TTM
209.66M
Debt / Equity
2.12
ROE
3.38%
Net Debt
351.93M
ROCE
4.01%
Diluted EPS TTM
0.23

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -47.41M -12.51M -28.81M -17.61M -0.57M
Minority interest -0.41M -0.42M -3.55M 45.20M 64.50M
Net income -48.62M -16.38M -81.02M -14.30M -0.78M
Selling general administrative 209.81M 170.52M 138.38M 103.20M 72.26M
Gross profit 209.66M 186.39M 135.19M 107.38M 83.29M
Reconciled depreciation 35.47M 39.30M 30.98M 16.51M 12.47M
Ebit 27.23M 15.87M -2.62M 4.36M 10.68M
Ebitda 62.70M 57.09M 28.36M 20.86M 23.15M
Depreciation and amortization 35.47M 41.22M 30.98M 16.51M 12.47M
Operating income 27.23M 15.87M -2.62M 4.36M 7.75M
Other operating expenses 894.41M 916.66M 783.24M 705.25M 517.59M
Interest expense 27.37M 24.70M 26.30M 14.49M 8.02M
Tax provision 1.21M 3.87M 52.22M -3.31M -0.66M
Interest income - - - 14.65M 7.98M
Net interest income -27.37M -24.70M -26.30M -14.49M -8.02M
Non recurring 47.26M - - - -
Income tax expense 1.21M 3.87M 52.22M -3.31M -0.66M
Total revenue 921.51M 932.53M 780.05M 709.43M 528.61M
Total operating expenses 182.56M 170.52M 138.38M 103.20M 72.26M
Cost of revenue 711.85M 746.13M 644.86M 602.05M 445.33M
Total other income expense net -74.64M -28.39M -26.19M -21.97M -3.58M
Net income from continuing ops -48.62M -16.38M -81.02M -14.30M 0.09M
Net income applicable to common shares -48.21M -15.97M -77.47M -11.45M -0.78M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 868.23M 818.90M 819.59M 771.59M 672.73M
Intangible assets 159.73M 172.48M 190.66M 213.00M 119.96M
Other current assets 12.64M 8.24M 8.90M 8.31M 7.07M
Total liab 645.23M 607.10M 564.37M 477.57M 344.42M
Total stockholder equity 221.21M 209.92M 252.83M 262.41M 283.11M
Other current liab 34.06M 21.15M 28.20M 20.26M 13.04M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -160.60M -162.73M -114.53M -93.38M -15.90M
Other liab - 1.02M 0.46M 1.40M 0.12M
Good will 199.40M 183.31M 231.11M 231.16M 231.04M
Other assets - 1.37M 2.02M 0.02M 62.99M
Cash 116.37M 101.27M 79.41M 33.46M 27.27M
Total current liabilities 189.53M 149.49M 98.10M 101.10M 73.01M
Net debt 351.93M 370.67M 401.25M 354.33M 252.46M
Short term debt 16.20M 15.35M 14.85M 12.71M 8.44M
Short long term debt 8.60M 8.75M 8.35M 7.79M 3.82M
Short long term debt total 468.30M 471.93M 480.66M 387.78M 279.73M
Other stockholder equity 383.49M 374.85M 368.01M 356.44M 300.12M
Property plant equipment - 73.39M 97.10M 63.15M 73.31M
Total current assets 430.83M 370.11M 298.69M 242.30M 185.42M
Net tangible assets - -145.86M -168.95M -181.75M -67.89M
Net receivables 142.51M 118.00M 113.95M 102.75M 71.38M
Long term debt 437.82M 443.28M 448.47M 355.98M 251.38M
Inventory 159.31M 142.60M 96.44M 97.77M 79.70M
Accounts payable 139.26M 113.00M 55.06M 68.13M 51.54M
Noncontrolling interest in consolidated entity - 1.87M 2.39M 31.61M 45.20M
Accumulated other comprehensive income -1.71M -2.22M -0.68M -0.69M -1.13M
Common stock total equity - 0.03M 0.03M 0.03M 0.03M
Retained earnings total equity - -162.73M -114.53M -93.38M -15.90M
Non currrent assets other 2.08M 1.37M 2.02M 1.87M 3.21M
Non current assets total 437.39M 448.78M 520.90M 529.30M 487.31M
Capital lease obligations 21.89M 19.91M 23.84M 24.04M 24.53M
Long term debt total - 443.28M 448.47M 355.98M 254.71M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -11.97M -26.14M -118.02M -195.03M -100.00M
Change to liabilities 51.24M -12.13M 25.98M -7.51M 18.59M
Total cashflows from investing activities -11.97M -26.14M -118.02M -195.03M -100.00M
Net borrowings -9.09M 43.57M -2.91M 134.54M 67.11M
Total cash from financing activities -13.71M 48.33M 128.76M 135.06M 140.97M
Change to operating activities -6.21M 5.48M 9.10M -1.54M 4.31M
Net income -48.62M -16.38M -81.02M -14.30M 0.09M
Change in cash 21.86M 45.95M 6.18M -39.09M 28.46M
Begin period cash flow 79.41M 33.46M 27.27M 66.36M 37.90M
End period cash flow 101.27M 79.41M 33.46M 27.27M 66.36M
Total cash from operating activities 48.02M 23.77M -4.60M 20.83M -12.41M
Issuance of capital stock - - 0.00M 0.00M 73.91M
Depreciation 35.47M 39.30M 30.98M 16.51M 12.47M
Other cashflows from investing activities - 5.13M -95.63M -184.75M -92.82M
Change to inventory -46.30M 1.28M -17.85M 30.45M -36.61M
Change to account receivables -4.14M -11.20M -31.65M -14.12M -14.21M
Sale purchase of stock -3.86M 0.01M 9.27M 2.32M 75.34M
Other cashflows from financing activities 58.24M 647.33M 968.80M 813.12M 535.22M
Change to netincome 58.68M 17.00M 16.90M 7.57M 3.40M
Capital expenditures 11.97M 31.27M 118.46M 10.28M 7.18M
Change receivables -4.14M -11.20M -31.65M -14.12M -14.21M
Cash flows other operating 1.69M 2.11M 52.07M 2.24M 3.86M
Exchange rate changes - - - - -0.09M
Cash and cash equivalents changes 22.34M 45.96M 6.14M -39.13M 28.56M
Change in working capital 1.90M -16.57M -22.96M 7.19M -30.81M
Stock based compensation 11.36M 9.43M 9.17M 7.36M 3.81M
Other non cash items 47.32M 4.50M 7.73M 7.54M 2.87M
Free cash flow 36.05M -7.50M -123.06M 10.56M -19.59M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR
-0.23
0.70%
32.85 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
169.42 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
-
-%
21.27 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-0.54
1.24%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

PetIQ Inc

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

230 East Riverside Drive, Eagle, ID, United States, 83616

208 939 8900

1121

Name Title Year Born
Mr. McCord Christensen Chairman & CEO 1972
Mr. Michael A. Smith Pres & COO 1978
Mr. Robert Michael Herrman Exec. VP, Gen. Counsel & Corp. Sec. 1969
Mr. Zvi Glasman Chief Financial Officer 1964
Mr. John Pearson Sr. VP & Head of Services Division NA
Mr. McCord Christensen Chairman of the Board & CEO 1972
Mr. Michael A. Smith President & COO 1978
Mr. William J. Carter Executive VP & General Counsel NA
Mr. John Pearson Executive Vice President of Services & Manufactured Products NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…